Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 8Leukemia 8Myeloproliferative Disorders 6Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Recurrence 5Primary Myelofibrosis 5Lymphoma, T-Cell 5Lymphoma 5Hodgkin Disease 5Multiple Myeloma 4Graft vs Host Disease 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Follicular 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Burkitt Lymphoma 2Breast Neoplasms 2

Interventions

ruxolitinib 1entinostat 1cemiplimab 1avelumab 1Pemetrexed 1Cyclophosphamide 1Cryosurgery 1Cisplatin 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × ruxolitinib × Lymphoid × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡